Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRMDNASDAQ:SBBPNASDAQ:SBTXNASDAQ:SVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$9.12+0.7%$8.71$3.61▼$13.85$594.46M1.571.04 million shs664,844 shsSBBPStrongbridge Biopharma$2.00$2.09$1.85▼$4.26$135.66M1.58866,464 shs684,684 shsSBTXSilverback Therapeutics$13.77-5.9%$12.57$2.80▼$8.97$496.52M0.6337,931 shs970,719 shsSVRASavara$3.26+2.2%$2.78$2.26▼$5.31$562.78M0.521.31 million shs369,593 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix-0.44%+11.30%+34.42%-25.49%+70.62%SBBPStrongbridge Biopharma0.00%0.00%0.00%0.00%0.00%SBTXSilverback Therapeutics0.00%-7.46%+10.25%-4.71%+64.91%SVRASavara+0.31%+4.59%+9.62%+17.28%-27.66%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRMDCorMedix2.5378 of 5 stars4.61.00.00.02.90.00.6SBBPStrongbridge BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASVRASavara1.4605 of 5 stars3.40.00.00.01.41.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRMDCorMedix 3.14Buy$14.5058.99% UpsideSBBPStrongbridge Biopharma 0.00N/AN/AN/ASBTXSilverback Therapeutics 0.00N/AN/AN/ASVRASavara 2.83Moderate Buy$8.83170.96% UpsideCurrent Analyst Ratings BreakdownLatest SBBP, SVRA, CRMD, and SBTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2025CRMDCorMedixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.004/8/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/28/2025SVRASavaraHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/26/2025CRMDCorMedixRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$12.00 ➝ $12.003/26/2025CRMDCorMedixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $12.003/25/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/7/2025CRMDCorMedixLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/7/2025CRMDCorMedixLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$18.003/5/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRMDCorMedix$43.47M13.67N/AN/A$1.28 per share7.13SBBPStrongbridge Biopharma$30.73M4.41N/AN/A$0.98 per share2.04SBTXSilverback TherapeuticsN/AN/AN/AN/A$7.41 per shareN/ASVRASavaraN/AN/AN/AN/A$1.04 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRMDCorMedix-$46.34M-$0.33N/A9.70N/AN/A-79.21%-64.68%5/8/2025 (Estimated)SBBPStrongbridge Biopharma-$45.08M-$0.78N/AN/AN/A-115.67%-66.82%-36.21%N/ASBTXSilverback Therapeutics-$89.48M-$2.42N/A∞N/AN/A-29.62%-28.20%N/ASVRASavara-$54.70M-$0.47N/AN/AN/AN/A-58.89%-46.44%5/8/2025 (Estimated)Latest SBBP, SVRA, CRMD, and SBTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CRMDCorMedix$0.20N/AN/AN/A$38.90 millionN/A5/8/2025Q1 2025SVRASavara-$0.12N/AN/AN/AN/AN/A3/27/2025Q4 2024SVRASavara-$0.11-$0.13-$0.02-$0.13N/A$0.27 million3/25/2025Q4 2024CRMDCorMedix$0.17$0.22+$0.05$0.22$27.46 million$30.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRMDCorMedixN/AN/AN/AN/AN/ASBBPStrongbridge BiopharmaN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRMDCorMedixN/A3.963.60SBBPStrongbridge Biopharma0.383.002.95SBTXSilverback TherapeuticsN/A67.8767.87SVRASavara0.1317.7017.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRMDCorMedix34.18%SBBPStrongbridge Biopharma52.03%SBTXSilverback Therapeutics74.89%SVRASavara87.93%Insider OwnershipCompanyInsider OwnershipCRMDCorMedix5.20%SBBPStrongbridge Biopharma5.10%SBTXSilverback Therapeutics34.40%SVRASavara5.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRMDCorMedix3065.18 million57.52 millionOptionableSBBPStrongbridge Biopharma7267.83 millionN/AOptionableSBTXSilverback Therapeutics8336.06 million23.65 millionNot OptionableSVRASavaraN/A172.63 million162.82 millionOptionableSBBP, SVRA, CRMD, and SBTX HeadlinesRecent News About These CompaniesMaharashtra News: Palghar MP Hemant Savara Stops To Help Injured Woman On Mumbai-Ahmedabad Highway (VIDEO)April 28 at 8:07 AM | freepressjournal.inSwift Action by MP Dr Hemant Savara Saves Road Accident VictimApril 28 at 8:07 AM | devdiscourse.comSavara: Make-It-Or-Break-It Molbreevi BLA FilingApril 21, 2025 | seekingalpha.comJPMorgan Chase & Co. Grows Stock Position in Savara Inc (NASDAQ:SVRA)April 21, 2025 | marketbeat.comSavara (NASDAQ:SVRA) Shares Up 4.1% - Here's What HappenedApril 17, 2025 | marketbeat.comAffinity Asset Advisors LLC Lowers Stock Position in Savara Inc (NASDAQ:SVRA)April 17, 2025 | marketbeat.comSavara Inc. Announces Equity Awards for New EmployeesApril 16, 2025 | msn.comSavara Inc (NASDAQ:SVRA) Shares Purchased by Vanguard Group Inc.April 16, 2025 | marketbeat.comSavara Inc (NASDAQ:SVRA) Receives Average Rating of "Moderate Buy" from BrokeragesApril 13, 2025 | marketbeat.comSavara Announces New Employment Inducement GrantApril 11, 2025 | businesswire.comWellington Management Group LLP Lowers Stock Holdings in Savara Inc (NASDAQ:SVRA)April 11, 2025 | marketbeat.comSavara Inc (NASDAQ:SVRA) Shares Purchased by ADAR1 Capital Management LLCApril 9, 2025 | marketbeat.comSavara announces encore presentations from Molgramostim Phase 3 IMPALA-2 trialApril 8, 2025 | markets.businessinsider.comSavara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific ConferencesApril 7, 2025 | businesswire.com259,798 Shares in Savara Inc (NASDAQ:SVRA) Bought by Raymond James Financial Inc.April 7, 2025 | marketbeat.comTuesday 4/1 Insider Buying Report: NTAP, SVRAApril 4, 2025 | nasdaq.comSAVARA Earnings Preview: Recent $SVRA Insider Trading, Hedge Fund Activity, and MoreApril 2, 2025 | nasdaq.comEvercore ISI Keeps Their Hold Rating on Savara (SVRA)April 1, 2025 | markets.businessinsider.comSavara Reports 2024 Financial Results and Provides Updates on MOLBREEVI ProgressApril 1, 2025 | msn.comWhat is HC Wainwright's Estimate for Savara Q1 Earnings?March 31, 2025 | marketbeat.comSavara (NASDAQ:SVRA) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPSMarch 29, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSBBP, SVRA, CRMD, and SBTX Company DescriptionsCorMedix NASDAQ:CRMD$9.12 +0.06 (+0.66%) Closing price 04:00 PM EasternExtended Trading$9.14 +0.02 (+0.26%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Strongbridge Biopharma NASDAQ:SBBPStrongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.Silverback Therapeutics NASDAQ:SBTX$13.77 -0.87 (-5.94%) As of 04/25/2025Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Savara NASDAQ:SVRA$3.26 +0.07 (+2.19%) Closing price 04:00 PM EasternExtended Trading$3.28 +0.02 (+0.64%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coca-Cola Company Stock Can Bubble to New Highs This Year Intel: Good Quarter, Bad Vibes, Guidance Rattles Investors Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet Domino’s Pizza Builds Leverage: Analysts Raise Price Targets 5 Mid-Cap Stocks Insiders Are Buying This Year Alphabet Rebounds After Strong Earnings and Buyback Announcement Occidental’s Hidden Gem: How OxyChem Could Boost Profits T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
